Balanced View on AptarGroup: Solid Underlying Pharma Performance Offset by Near-Term Headwinds and Underwhelming Beauty & Closures, Justifying a Hold Rating

In a report released on February 6, George Staphos from Bank of America Securities reiterated a Hold rating on AptarGroup, with a price target of $147.00.

George Staphos has given his Hold rating due to a combination of factors, balancing AptarGroup’s attractive strengths with notable near‑term challenges. He highlights that the Pharma segment is performing well beneath the surface, with solid EBITDA and robust core growth once the drag from emergency medicines is stripped out, but he also notes that the sharp decline in those emergency products will weigh disproportionately on earnings in the first half of the year.

At the same time, Staphos points out that the Beauty and Closures divisions underwhelmed, and he remains cautious until they show more consistent progress toward their targeted margin ranges, even though he expects better EBITDA by the third quarter. He also trims his 2026 earnings forecast to reflect these softer businesses and the heavier first‑half headwind, and while he raises his price objective after rolling valuation to later‑year estimates, he concludes that foreign‑exchange effects and the reliance on seasonal cold/flu and holiday fragrance demand limit upside, supporting a Neutral stance rather than a Buy.

ATR’s price has also changed slightly for the past six months – from $138.540 to $134.310, which is a -3.05% drop .